Cestex® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Cestex®

Active ingredient

Epsiprantel

Application type

NADA

Sponsor

Zoetis Inc.

Applications on record

1

First published

June 1, 2016

Adverse event reports

Source: openFDA VeDDRA

754

Reports mentioning this ingredient

December 20, 1990 – January 19, 2026

70

Classified serious

per reporter assessment

376

Lack of expected efficacy

resistance signal

30

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “EPSIPRANTEL”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Lack of efficacy (endoparasite) - tapeworm	285
Vomiting	81
No sign	48
Unclassifiable adverse event	45
Death	42
Depression	41
Anorexia	36
Diarrhoea	30
Accidental exposure	29
Fever	21
Ataxia	21
Convulsion	20
Lack of efficacy - NOS	16
Bloody diarrhoea	12
Lack of efficacy (tapeworm)	11
Anaemia NOS	10
Lethargy (see also Central nervous system depression in 'Neurological')	10
Overdose	10
Dehydration	9
Hypersalivation	8

Species affected

Source: openFDA VeDDRA

Dog 466 Cat 224 Human 50 Other 3

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient